EGFR and cancer: Our analysis revealed that cancer cells with decreased NF2 expression display high sensitivity to DNA synthesis inhibition (Cytarabine, Oxaliplatin, and 5-Fluorouracil) [26] and epidermal growth factor receptor (EGFR) targeted therapies (Gefitinib and Lapatinib) [27,28,29] (Figure 2G).